Determination of exemestane, a new aromatase inhibitor, in plasma by high-performance liquid chromatography with ultraviolet detection.
A sensitive and selective high-performance liquid chromatographic method for the determination of 6-methylen-androsta-1,4-diene-3,17-dione (exemestane) and its 17-dihydro metabolite in human plasma has been developed. The analytes and internal standard (Norgestrel) were extracted from plasma samples with a methylene chloride-iso-octane mixture; the organic phase was dried and the residue was reconstituted with an acetonitrile-water mixture, then analyzed by reversed-phase liquid chromatography. Quantification was achieved by ultraviolet detection of the eluate. The linearity, precision and accuracy of the method were evaluated. No interference from the constituents of human blank plasma was observed. The lower limit of quantification was 10 ng/ml plasma. The suitability of the method for in vivo samples was checked by analysis of plasma samples drawn from healthy male volunteers who had received a 200-mg single oral dose of the test compound.
Breda
M
M
Pharmacokinetics and Metabolism Department, R&D, Farmitalia Carlo Erba, Nerviano, Milan, Italy.
Pianezzola
E
E
Benedetti
M S
MS
D000730:Androstadienes / Q000097:blood*; D047072:Aromatase Inhibitors; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D006801:Humans; D008297:Male; D015203:Reproducibility of Results; D013056:Spectrophotometry, Ultraviolet
D000730:Androstadienes; D047072:Aromatase Inhibitors; C056516:exemestane